Liver receptor homolog-1 (LRH-1) is an orphan nuclear receptor that belongs to the NR5A subgroup of nuclear receptors. LRH-1 induces key genes to regulate metabolic process, ovarian function, cancer cell proliferation, and steroidogenesis. In the breast, LRH-1 modulates and synergizes with endogenous estrogen signaling to promote breast cancer cell proliferation. We used small interfering RNA knockdown strategies to deplete LRH-1 in breast cancer cells and followed with microarray analysis to identify LRH-1-dependent mechanisms. We identified key genes involved in TGF-␤ signaling to be highly responsive to LRH-1 knockdown. This relationship was validated in 2 breast cancer cell lines overexpressing LRH-1 in vitro and in a novel transgenic mouse with targeted LRH-1 overexpression in mammary epithelial cells. Notably, TGF-␤ signaling was activated in LRH-1-overexpressing breast cancer cells and mouse mammary glands. Further analyses of mammary gross morphology revealed a significant reduction in mammary lateral budding after LRH-1 overexpression. These findings suggest that the altered mammary morphogenesis in LRH-1 transgenic animals is mediated via enhanced TGF-␤ expression. The regulation of TGF-␤ isoforms and SMAD2/ 3-mediated downstream signaling by LRH-1 also implicates a potential contribution of LRH-1 in breast cancer. Collectively, these data demonstrate that LRH-1 regulates TGF-␤ expression and downstream signaling in mouse mammary glands. (Endocrinology 155: 1606 -1617, 2014) L iver receptor homolog-1 (LRH-1) is a monomeric nuclear receptor that belongs to the NR5A subgroup of nuclear receptors. LRH-1 regulates transcription of key genes to regulate metabolic processes including bile acid synthesis, reverse cholesterol transport, and glucose homeostasis (for a review, see Ref. 1). Its high expression in granulosa cells in the ovary and recent functional studies in ovary-specific knockout mice demonstrate that it is essential for both ovulation and pregnancy (2, 3). LRH-1 is also highly expressed in the intestine, gastric system, and pancreas, where it regulates cell proliferation (4 -6). In these tissues, there is growing evidence that LRH-1 contributes to tumor formation, as it is involved in cell cycle progression to promote tumor proliferation (6). In ovarian and breast tumor tissue, LRH-1 is involved in the upregulation of enzymes such as steroidogenic acute regula- Abbreviations: ACTA2, smooth muscle actin ␣2; ANXA2, annexin 2; ChIP, chromatin immunoprecipitation; Dox, doxycycline; ER, estrogen receptor; GFP, green fluorescent protein; hLRH-1, human liver receptor homolog-1; HTRA1, HtrA serine peptidase 1; IHC, immunohistochemical; IPA, ingenuity pathway analysis; ITGB1, integrin-␤1; KRT18, cytokeratin 18; LRH-1, liver receptor homolog-1; MMP3, matrix metalloproteinase 3; NR4A1, nuclear receptor 4A1; siRNA, small interfering RNA; TBS, Tris-buffered saline; TNFRSF12a, TNF receptor superfamily, member 12A; TP53, tumor protein p53; TPSAB1/2, tryptase ␣ and ␤
L
iver receptor homolog-1 (LRH-1) is a monomeric nuclear receptor that belongs to the NR5A subgroup of nuclear receptors. LRH-1 regulates transcription of key genes to regulate metabolic processes including bile acid synthesis, reverse cholesterol transport, and glucose homeostasis (for a review, see Ref. 1) . Its high expression in granulosa cells in the ovary and recent functional studies in ovary-specific knockout mice demonstrate that it is essential for both ovulation and pregnancy (2, 3) . LRH-1 is also highly expressed in the intestine, gastric system, and pancreas, where it regulates cell proliferation (4 -6) . In these tissues, there is growing evidence that LRH-1 contributes to tumor formation, as it is involved in cell cycle progression to promote tumor proliferation (6) . In ovarian and breast tumor tissue, LRH-1 is involved in the upregulation of enzymes such as steroidogenic acute regula-tory protein and aromatase, both of which regulate ratelimiting processes in the production of steroid hormones (7, 8) .
The best characterized action of LRH-1 in breast cancer is the modulation of endogenous estrogen signaling: LRH-1 is expressed in breast adipose stromal cells and breast cancer-associated fibroblasts, where it stimulates expression of aromatase, the rate-limiting step in estrogen synthesis (9) . In breast cancer cell lines, LRH-1 regulates expression of estrogen receptor (ER) ␣ (10) and is itself an ER␣ target gene (11) . LRH-1 can also directly stimulate expression of ER␣ target genes such as GREB1 and pS2 by binding to estrogen response elements within their promoters (12) . Thus, LRH-1 expression in breast cancer cells and cancer-associated fibroblasts mediates a positive feedback loop that contributes to increased estrogen synthesis and action.
Localization of LRH-1 in human breast tissue demonstrates nuclear expression in the luminal epithelium of normal mammary glands and increased levels in both ERpositive and ER-negative tumors and associated stroma (7) . Functional studies in cell lines demonstrate that overexpression of LRH-1 increases estrogen-mediated cell proliferation (10) . LRH-1 also has direct, estrogen-independent effects on breast cancer cell proliferation (12) . In addition, overexpression or knockdown of LRH-1 in ERpositive, ER-negative, and normal mammary epithelial cell lines demonstrates a role in cell proliferation, migration, and invasion associated with remodeling of the actin cytoskeleton and cleavage of E-cadherin (13) . Although the mechanisms of these effects are currently unclear, they may involve stimulation of matrix metalloprotease activity and/or direct induction of cell cycle-associated genes. Aside from genes involved in estrogen signaling, few LRH-1 target genes have been identified in normal or breast cancer epithelial cells. To obtain an understanding of LRH-1-dependent mechanisms in breast cancer cells, we used small interfering RNA (siRNA) knockdown strategies followed by microarray analysis to identify novel LRH-1 target genes in MCF-7 cells. We found that genes involved in TGF-␤ signaling were highly responsive to LRH-1 knockdown. This LRH-1-dependent regulation of TGF-␤ family members was observed in both human breast cancer cells in vitro and in a transgenic mouse with targeted LRH-1 overexpression in mammary glands. The induction of LRH-1 in mammary glands of adult transgenic mice caused alterations in Smad2/3-mediated TGF-␤ signaling pathways and abnormal mammary ductal formation. Collectively, these data demonstrate the importance of LRH-1 in regulating ductal morphogenesis to promote normal mammary gland formation. The regulation of expression of TGF-␤ isoforms and Smad2/3-mediated signaling by LRH-1 also indicates a potential contribution in breast cancer.
Materials and Methods

Generation and genotyping of transgenic mice
All studies involving mice were regulated under the protocol approved by the Monash Medical Centre (Ethics: MMCB10/ 12). The pTetOLRH-1 transgene was generated from a construct containing the human LRH-1 open reading frame (9) . In brief, a Kozak sequence was introduced by site-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) and primers F-Kozak (5Ј-TTAAGCCAAAG AACTGCCTATAATTTCACTCACCATGGCTTCTAATTCA-GATACTGGGGATTTACAAG-3Ј) and R-Kozak (5Ј-CTTGTA AATCCCCAGTATCTGAATTAGAAGCCATGGTGAGTGAA ATTATAGGCAGTTCTTTGGCTTAA-3Ј). The LRH-1 open reading frame containing the Kozak sequence was then subcloned into the multiple cloning site of the pTRE-Tight-BI-DsRed Express vector (Clontech) after NotI restriction digest. Orientation of the insert was verified by digesting the vector with BamHI. The vector was then linearized using ApaLI and gel purified. The pTetOLRH-1 founder mice were generated by pronuclear injection (MouseWorks Service) of the purified transgene, and complete transgene insertion was verified using primers that spanned the 3Ј end of the DsRed open reading frame (L1) (forward 5Ј-5Ј-GCCGATGAACTTCACCTTGT-3Ј and reverse 5Ј-CGAGGACGTCATCAAGGAGT-3Ј) and the 3Ј end of the LRH-1 open reading frame (L2) (forward 5Ј-TCGACCACATT-TACCGACAA-3Ј and reverse 5Ј-TGGCTGATTATGATC-CTCTGG-3Ј). MMTVrtTA-pTetOLRH-1 ( MMTV tet-LRH-1) double-transgenic mice were generated by crossing pTetOLRH-1 founder females with MMTVrtTA males. Genotyping of double-transgenic animals was performed using the primers for LRH-1 listed above and MTB forward (TGCCGCCATTATTACGACAAGC) and reverse (ACCGTACTCGTCAATTCCAAGGG). Only female MMTV tet-LRH-1 mice were selected for this study unless otherwise stated.
Induction of LRH-1 transgene expression
To induce the LRH-1 transgene, doxycycline hyclate (631311; Clontech) was supplied in drinking water at a 2 mg/mL concentration with 3% sucrose. The control cohorts were provided with 3% sucrose in drinking water. The water was replaced every 3 days and kept under light-sensitive conditions.
Determination of stage of mouse estrous cycle
Vaginal smears were performed using saline and a plastic transfer pipette. Sloughed cells were spread on a glass slide, stained with hematoxylin and eosin, and examined by light microscopy to determine the stage of the estrous cycle (proestrus, oestrus, metestrus I, metestrus II, or diestrus).
Mammary gland whole-mount analysis
The fourth inguinal mammary glands were harvested and spread onto slides, and fixed with Carnoy's fixative (60% ethanol, 30% chloroform, and 10% glacial acetic acid) for 2 to 3 hours. The glands were placed in 70% ethanol for 15 minutes followed by 5 minutes each in 50% ethanol, 25% ethanol, and double-distilled water before staining overnight with carmine doi: 10.1210/en. endo.endojournals.orgalum. The mammary glands were dehydrated sequentially in graded ethanol, washed, and cleared in histolene to dissolve the fat in the gland. The slides were maintained in DPX mounting media for analysis under a light microscope. The numbers of primary and secondary branches and ductal ends were counted for the entire gland. The mammary gland tree occupancy was then estimated according to the sections occupied. Data points from all mice in the same group were averaged and plotted.
Immunohistochemical (IHC) analysis
Sections of 5-m thickness were cut from formalin-fixed, paraffin-embedded, inguinal mammary glands. Before staining, the sections were dewaxed and rehydrated in graded ethanol washes. Antigen retrieval was performed by immersing slides in 600 mL of Target Retrieval Solution (Dako) and heating in a 1000-W microwave oven at 100% power for 5 minutes, standing at room temperature for 5 minutes, and then heating for an additional 5 minutes at 40% power, before cooling at room temperature for 1 hour. Sections were then treated with 3% hydrogen peroxide for 5 minutes to block endogenous peroxidase activity. To block endogenous avidin and biotin in the sections, the Avidin/Biotin Blocking Kit (Vector Laboratories) was used. The sections were then incubated with specific primary antibodies ( 
Western blotting
Protein lysates were prepared by placing the mammary glands or breast cancer cells in protein lysis buffer (5 mM HEPES, 137 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 mM NaF, 2 mM EDTA, 10 mM sodium pyrophosphate, 1% Nonidet P-40, 10% glycerol, and protease inhibitors [Roche]). The tissue was then homogenized using the QIAGEN TissueLyser LT. After homogenizing, the sample was centrifuged (full speed for 15 minutes) and incubated in 4°C for 15 minutes on ice. The supernatant was then collected and used for downstream protein applications. Protein concentrations in these lysates were measured by a BCA Protein Assay Kit (Pierce Biotechnology). Equal amounts (40 g) of total cellular protein extract were electrophoresed on a 10% SDS-PAGE gel and transferred onto a nitrocellulose membrane (Hybond-C Super, RPN203G; Amersham). Membranes were blocked with 5% (wt/vol) milk protein in Tris-buffered saline (TBS) containing 0.05% Tween 20. Blots were then incubated with the primary antibodies as indicated, washed in TBS containing 0.1% Tween 20, and probed with primary antibodies. Secondary IgG-conjugated mouse or rabbit antibodies, and Alexa Fluor 700 (Invitrogen) were used at a dilution of 1:10 000 to visualize protein bands. Band intensities were quantified using the Odyssey infrared imaging system and Odyssey 3.0 Software (LI-COR Biosciences). Blots shown are representative of a minimum of 3 separate experiments.
Quantitative RT-PCR
Total RNA was prepared from mouse mammary tissue or breast cancer cells using an RNeasy Kit (74106; QIAGEN), treated with DNaseI (AM1906; Ambion), and quantified using a NanoDrop 1000 spectrophotometer. First-strand cDNA synthesis using 1.0 g of total RNA was performed using AMV Reverse Transcriptase (M5101; Promega) primed by random hexamers. PCRs were performed using TaqMan probes (Applied Biosystems) against LRH-1 (Hs00187067_m1), nuclear receptor 4A1 (NR4A1) (Hs00374226_m1), tumor protein p53 (TP53) (Hs01034249_m1), integrin-␤1 (ITGB1) (Hs00559595_m1), cytokeratin 18 (KRT18) (Hs02827483_g1), annexin A2 (ANXA2) (Hs00743063_s1), matrix metalloproteinase 3 (MMP3) (Mm00440295_m1), smooth muscle actin ␣2 (ACTA2) (Mm00808218_g1), tryptase ␣ and ␤ 1/2 (TPSAB1/20 (Mm00491950_m1), TNF receptor superfamily, member 12A (TNFRSF12a) (Mm00489103_m1), and HtrA serine peptidase 1 (HTRA1) (Mm00479892_m1) and TaqMan Gene Expression Master Mix (Applied Biosystems). Other genes were analyzed using Power SYBR Green PCR Mix (Applied Biosystems) with the following primers: 18s, sense CGGCTACCACATCCAAGGAA and antisense GCTGGAATTACCGCGGCT; mouse TGF-␤1, sense AGC CCGAAGCGGACTACTAT and antisense TTCCACAT GTTGCTCCACAC; mouse TGF-␤2, sense TTTAAGAGGGATCT-TGGATGGA and antisense AGAATGGTCAGTGGTTCCAGAT; and mouse TGF-␤3, sense CGCACAGAGCAGAGAATTGA and antisense GTGACATGGACAGTGGATGC. mRNA was quantified by an ABI Prism 7900HT real-time PCR system. Fold changes in expression of LRH-1 were calculated using the ⌬⌬C t method (14) 
Knockdown and overexpression of LRH-1 in MCF-7 cells
To reduce basal LRH-1 expression levels in the MCF-7 breast cancer cell line, the SureSilencing short hairpin RNA plasmids (KH05888G; SABiosciences) designed to specifically knock down the expression of LRH-1 by RNA interference were used as verified previously (13) . MCF-7 cells were cultured in DMEM supplemented with 10% fetal bovine serum, 50 U/mL penicillin, and 50 g/mL streptomycin at 37°C in 5% CO 2 . Cells were transfected with either pGeneClip hMGFP-LRH-1 or pGeneClip hMGFP encoding a scrambled short hairpin RNA sequence as a negative control using the Nucleofector Device Kit V (Amaxa Biosystems), according to the manufacturer's instructions. Green fluorescent protein (GFP)-positive cells were collected by fluorescence-activated cell sorting 24 hours after transfection. To overexpress LRH-1, the pcDNA3.1 plasmid expression construct containing the full-length sequence of human LRH-1 was transfected using Amaxa transfection as described previously (13) . Control transfections were performed with the pcDNA3.1 vector alone, mRNA was isolated for quantitative PCR analysis, and protein lysates were extracted for Western blot analysis 24 hours posttransfection.
Expression profiling and analysis
Gene expression profiling (human whole-genome HumanHT12 v2 BeadChip arrays, containing 46 325 probes; Illumina) was conducted in 2 separate experiments: (1) in MCF-7 cells in which the effects of LRH-1 knockdown on global gene expression were determined and (2) in mammary tissue in which human LRH-1 was overexpressed using the doxycycline (Dox)-inducible transgenic mouse described above. In MCF-7 cells, 10 transfections were performed and pooled per condition, GFPpositive cells were isolated by fluorescence-activated cell sorting, and RNA was isolated.
For the transgenic mouse studies, RNA was isolated from mammary tissue from 3-month-old control and Dox-treated LRH-1 transgenic mice (n ϭ 3). Arrays were performed for individual samples to analyze gene expression per animal (MouseWG-6 v2 Expression BeadChip; Illumina).
Expression profiling was performed at the Australian Genome Research Facility(Parkville, Australia). For the MCF-7 cell microarray, samples were normalized by quantile normalization using the lumi package in R statistical software and subsequently imported into GeneSpring GX for analysis. In each case, genes were considered differentially expressed between groups if the fold change (positive or negative) was Ն1.4. Ingenuity pathway analysis (IPA) (Ingenuity Systems) was used to identify gene networks according to biological functions and/or diseases in the IPA database. The significance value associated with a given function was expressed as a P value (calculated using a righttailed Fisher exact test) by comparing the number of LRH-1-regulated genes associated with a given function with the total number of occurrences of those genes in all functional annotations in the IPA database.
For the mouse mammary microarray, raw signal intensity values were subjected to variance stabilization transformation including background correction, log2 transformation, and variance stabilization using the lumiR package of the R Bioconductor (15, 16) . ANOVA analysis of normalized probe intensity values was performed in Partek Genomic Suite software (version 6.6 build 6.12.0420; Partek Inc). ANOVA was used to calculate the significance of variation in normalized expression values between sample groups; fold change of gene expressions was calculated as the mean ratio. Probes with an unadjusted P value of Յ.05 (no false discovery rate correction was applied) and an absolute fold change of Ն1.5 were defined as differentially expressed. For both data sets, we used IPA to assess significant upstream regulators. The activation Z-score was calculated as a measure of the functional and translational activation in network and upstream regulator analysis. An absolute Z-score of Ͻ2 (inhibited) or Ͼ2 (activated) was considered significant.
Chromatin immunoprecipitation (ChIP)
The ChIP procedures were performed as described previously (12) . The precipitated chromatin was analyzed by quantitative real-time PCR to demonstrate relative occupancy. Primer sequences were as follows: LRH-1 RE1, sense ACTCTGCCTCCAACGTCACC and antisense GGCACCGCTTCTGTCCTTTC; LRH-1 RE2, sense CAATTACCACCATCTGATCTACC and antisense GGGATA GATAAGACGGTGGGAG; and negative, sense CTCACAGCAAT-TACCACCATC and antisense TTTGACTACCAGACTGAG-GAGCT; amplified at 58°C for 45 cycles. Primer sequences for LRH RE1 GREB1 were as described previously (12) .
Statistical analysis
All data are reported as means Ϯ SE for 3 or more separate experiments as indicated. Semiquantification of IHC staining and Sirius red staining was performed by 3 independent researchers. Statistical analyses for experiments comparing 2 groups were performed by a two-tailed Student independent t test using GraphPad Prism 5.0 (GraphPad Software, Inc), and a value of P Ͻ .05 was considered statistically significant.
Results
LRH-1 overexpression induces TGF-␤ isoforms and downstream signaling in vitro
To identify LRH-1-regulated genes in breast cancer epithelial cells, Illumina expression profiling was performed using RNA from GFP-sorted MCF-7 cells expressing either LRH-1 siRNA or control siRNA. Significant alterations were observed for 1200 genes, of which 726 were down-regulated and 474 were up-regulated ( Figure 1A) . Genes altered in expression were associated with processes regulating cellular morphology, movement, and interaction (Supplemental Table 1 published on The Endocrine Society's Journals Online web site at http://end.endojournals.org).
Detailed inspection of differentially expressed genes revealed a marked down-regulation of several genes involved in TGF-␤ signaling in cells expressing siRNA against LRH-1, including TGF-␤2), NR4A1, TP53, ITGB1, KRT18, and ANXA2 ( Figure 1A, n ϭ 6, red dots) . Transcript levels were normalized to 18s and are presented as fold change relative to those of controls. E, Western blot analysis of wholecell extracts collected 24 hours posttransfection with either LRH-1 pcDNA or empty vector reveals an increase in LRH-1 and active TGF-␤1, -2, and -3 protein expressions, normalized to that of ␤-tubulin. F, Quantification of LRH-1 and active TGF-␤1 protein expression, and quantification of active/inactive TGF-␤2 and -3 protein expression. G, Analysis of protein levels of phosphorylated (p) Smad2 and Smad3 reveals an increase after LRH-1 overexpression, normalized to ␤-tubulin. H, Quantification of phospho/total Smad2 and Smad3 protein expression. Data are presented as means Ϯ SEM. n ϭ 3 separate experiments. *, P Ͻ .05; **, P Ͻ .01; ***, P Ͻ .001.
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In addition, using IPA, we found a significant inhibition of TGF-␤1 as an upstream regulator, with a Z-score of Ϫ2.596. To confirm that these candidate genes were indeed down-regulated in LRH-1-siRNA cells, we performed real-time RT-PCR and observed a significant decrease in expression of LRH-1, TGF-␤2, NR4A1, TP53, ITGB1, KRT18, and ANXA2 in siRNA-LRH-1 cells compared with that in control siRNA cells ( Figure 1B , red dashed line represents 1.3-fold down-regulation). These results suggested that LRH-1 might modulate endogenous TGF-␤ signaling, and we therefore examined this potential relationship in detail.
We transiently overexpressed LRH-1 in 2 ER␣-positive breast cancer cell lines, MCF-7 and T47-D. LRH-1 mRNA levels were significantly increased in each cell line ( Figure  1, C and D) , although the absolute levels were higher in MCF-7 cells. Overexpression of LRH-1 significantly increased expression of TGF-␤1, -2, and -3 mRNA in MCF-7 and T47-D cells (Figure 1, C and D) . Furthermore, we also examined the expression levels of several genes involved in TGF-␤ signaling as observed in the microarray. We demonstrated a significant increase in NR4A1, TP53, ITGB1, and KRT18 in LRH-1-overexpressing MCF-7 and T47-D cell lines (Figure 1, C and D) . A significant increase in ANXA2 was only observed in T47-Dcells ( Figure 1D ). We observed differential expression of TGF-␤ isoforms in MCF-7 and T47-D cells.
LRH-1 overexpression increased protein expression of bioactive TGF-␤ isoforms in MCF-7 cells, and this correlated with reduced expression of their corresponding precursor isoforms ( Figure 1E ). In addition, we quantified LRH-1 and TGF-␤ relative intensity and demonstrated increased expression in LRH-1-overexpressing cells (Figure 1F) . Quantification of active/inactive relative intensity revealed increased TGF-␤ active forms in LRH-1-overexpressing cells ( Figure 1F ).
TGF-␤ isoforms initiate signaling via ligand-induced oligomerization of serine/threonine receptor kinases and phosphorylation of cytoplasmic signaling molecules Smad2 and Smad3. Carboxyl-terminal phosphorylation of Smad2 and Smad3 results in their partnering with the transducer Smad4, which causes subsequent translocation into the nucleus. To demonstrate activation of TGF-␤ signaling pathways, we analyzed the phosphorylation status of Smad2/3 in MCF-7 cells. In cells overexpressing LRH-1, an increase in Smad2 and Smad3 phosphorylation was observed with no change in the levels of total Smad2 and Smad3 ( Figure  1G ). Quantification of phosphorylated/total Smad levels reveals an increase in phosphorylated Smad2 and Smad3 in LRH-1-overexpressing MCF-7 cells ( Figure 1H ). Taken together, these results identify a novel association between LRH-1 and TGF-␤ in ER␣-positive breast cancer cells.
TGFB1 is a direct transcriptional target of LRH-1
Using the University of California, Santa Cruz genome browser (http://genome.ucsc.edu) to obtain the TGFB1 promoter sequence and BIOBASE transcription binding site analysis software Patch (http://www.gene-regulation. com/pub/programs.html), we identified potential LRH-1 consensus half sites (LRH-1 REs) within a region spanning 2 kb of the TGFB1 promoter. We selected 2 LRH-1 REs, LRH-1 RE1 (Ϫ682 bp) and LRH-1 RE2 (Ϫ1406 bp) from the start site (Figure 2A) . Furthermore, we selected a region that had no LRH-1 binding site, denoted "negative" (Figure 2A ). We demonstrated LRH-1 interaction on LRH-1 RE1 of the TGFB1 promoter region ( Figure 2B ). However, no interaction was observed on LRH-1 RE2 and the negative region. As shown previously, we observed interaction on the LRH-1 RE1 of the GREB1 promoter region ( Figure 2B ) (12) .
Generation of a transgenic mouse that inducibly expresses LRH-1 in mammary gland
To demonstrate that LRH-1 activates TGF-␤ signaling in vivo we generated a transgenic mouse in which human LRH-1 is expressed specifically in mammary epithelial cells in response to Dox. We first created a line in which human LRH-1 is expressed under the control of a tetra- transgene was undetectable in mammary RNA isolated from vehicletreated mice ( Figure 3C ). However, administration of 2 mg/mL Dox in drinking water from 56 days of age for short (3 weeks, n ϭ 14) or long (3 months, n ϭ 16) time frames resulted in significant expression of hLRH-1 at both time points ( Figure 3C ). Using an antibody that recognizes both mouse and human LRH-1, we confirmed that Dox treatment strongly induced LRH-1 protein expression in mammary gland, whereas endogenous expression of LRH-1 in liver and intestine was unaffected ( Figure  3D ). IHC analysis confirmed that Dox-induced hLRH-1 was expressed specifically in luminal epithelial and myoepithelial cells, as expected for MMTV-driven transgene expression ( Figure 3E ). LRH-1 expression was semiquantitated, and we observed a 1.5-fold increase in 3-weektreated animals and a 3-fold increase in 3-month-treated animals ( Figure  3F ; *, P Ͻ .05; **, P Ͻ .01).
LRH-1 overexpression induces TGF-␤ signaling in mouse mammary gland
To determine whether LRH-1 activates TGF-␤ signaling in mouse mammary cells, as it does in MCF-7 breast cancer cells, we performed Illumina expression profiling using whole mammary RNA isolated from vehicle-and Dox-treated MMTV tetLRH1 mice ( Figure 4A ). A total of 242 genes were significantly altered in the Dox-treated group, of which 120 were down-regulated and 122 were up-regulated ( Figure 4A ). Similar to MCF-7 data, genes whose expression were modulated by Dox included those associated with cellular movement, interaction, cell death survival, cancer, and embryonic development (Supplemental Table 2 ). A volcano plot was generated, and, again consistent with the MCF-7 data, genes involved in TGF-␤ signaling, including MMP3, which is involved in epithelial to mesenchymal transition (18) , ACTA2, which is required for breast can- Figure 3 . Characterization of LRH-1 mammary-specific overexpression mouse model. A, Doxinducible system is a bigenic system allowing inducible expression of the gene of interest. To obtain mammary epithelium-specific, Dox-controlled transgene expression, a MMTV-RTTA transgenic mouse line, expressing the RTTA transactivator under control of mammary-specific MMTV promoter, is mated with a LRH-1 transgenic line, leading to a Dox-inducible and mammary-specific LRH-1 overexpression mouse model. B, Mouse genotype was confirmed using PCR on DNA extracted from mouse tails. L1 and L2 PCRs were used to confirm the presence of the hLRH-1 construct. MTB PCR was used to confirm the presence of the MMTV-RTTA construct. Only double-transgenic (Tg) animals that were positive for the L1/L2 and MTB constructs were used for experiments. WT, wild-type. C, Real-time PCR on whole mammary lysates using a human LRH-1 probe revealed variable expression of the LRH-1 transcript in Dox-treated animals. D, Analysis of protein expression of LRH-1 protein in liver (Liv), intestine (Int), and mammary gland (Mam) showed an increase in LRH-1 protein in mammary lysate after Dox treatment, normalized to ␤-tubulin. E, IHC analysis on 5-m sections reveals an increase in LRH-1 immunostaining after Dox treatment and protein localization to luminal epithelial cells as indicated by the arrow. Rabbit IgG was used as a negative control. F, Quantification of LRH-1 immunostaining reveals an increase in LRH-1 expression after Dox treatment. Data are presented as means Ϯ SEM. n ϭ 7 per treatment. *, P Ͻ .05; ** P Ͻ .01. Scale bars correspond to 50 m. nd, not determined.
cer cell migration (19), TPSAB1/ 2, which activates TGF-␤1 (20) , TNFRSF12a, which is involved in breast cancer cell motility (21) , and HTRA1 which regulates angiogenesis through TGF-␤ signaling (22) , were significantly up-regulated in mammary glands of Dox-treated MMTV tetLRH1 mice ( Figures 3A, n ϭ  5, red dots, and 4A) .Using IPA, we demonstrated significant activation of TGF-␤1 as an upstream regulator with a Z-score of 2.524.
We confirmed that Dox treatment of MMTV tetLRH1 mice increased mRNA levels of TGF-␤1, -2, and -3 in mammary glands at both short and long time points (Figure 4 , B, D, and F) and demonstrated significant correlations between mRNA levels of hLRH-1 and TGF-␤1 (r ϭ 0.4917) ( Figure 4H ) and between hLRH-1 and TGF-␤2 (r ϭ 0.5661) ( Figure 4I ; dotted lines show 95% confidence limits). No correlation was observed between hLRH-1 and TGF-␤3 (data not shown). IHC analysis of mammary glands demonstrated increased immunostaining of TGF-␤ isoforms 1, 2,and3proteininluminalepithelialcells of Dox-treated MMTV tetLRH1 mice at 3-week and 3-month time points compared with that in age-matched control animals ( Figure 4 , C, E, and G and Supplemental Figure 2) .
The marked genes involved in TGF-␤ signaling observed in the mouse microarray were validated, and we demonstrated increased expression of MMP3, ACTA2, TB-SAB1/2, TNFRSF12a, and HTRA1 in 3-month Dox-treated animals ( Figure 5, A-E) .
Consistent with these findings, protein levels of TGF-␤1 and -2 and of active, phosphorylated Smad2 and Smad3, were all significantly increased in mammary lysates from Dox-treated MMTV tetLRH1 mice ( Figure 5, F and H) . Quantification of TGF-␤ isoform intensity revealed increased expression of TGF-␤1 and Microarray analysis revealed that genes involved in TGF-␤ signaling are upregulated in RNA extracted from whole mammary lysates of Dox-treated animals. A, Volcano plot of fold change (x-axis) and P value (y-axis). Gray dots represent all regulated genes, black dots represent genes significantly regulated, and red dots represent genes involved in TGF-␤ signaling. Black dotted lines represent a cutoff range of Ͼ1.5-fold and P Ͻ .05. B, D, and F, Real-time analysis of TGF-␤1, -2, and -3 using RNA extracted from whole mammary lysates of control animals or treated with Dox for 3 weeks or 3 months. C, E, and G, Immunostaining of TGF-␤1, -2, and -3 in 5-mm sections of mammary tissue from control animals or treated with Dox for 3 weeks. Inset, IgG negative for each antibody. H and I, Correlation of transcript expression levels of LRH-1 and TGF-␤1 (H) and TGF-␤2 (I). Data are presented as means Ϯ SEM. n ϭ 7 per treatment. *, P Ͻ .05; **, P Ͻ .01; ns, not significant. Scale bars correspond to 200 m. doi: 10.1210/en. endo.endojournals.org-2 ( Figure 5G ). In addition, quantification of phosphorylated/total Smad2 and Smad3 relative intensity revealed increased phosphorylated Smad2 and Smad3 in Doxtreated animals ( Figure 5I ). Finally, TGF-␤ is known to induce expression of collagen 1 via activation of the Smad pathway (23) . Accordingly, we demonstrated increased collagen expression, as determined by Sirius red staining, in mammary glands of Dox-treated MMTV tetLRH1 mice at both short and long time points (1.75-and 2.3-fold, respectively) compared with that for age-matched controls ( Figure 5 , J and K).
LRH-1 overexpression inhibits lateral bud formation
The primary actions of TGF-␤ in the regulation of mammary development processes include the regulation of ductal outgrowth, lateral branching, lactation, and apoptosis (24) . Indeed, overexpression of TGF-␤ in mice inhibits ductal morphogenesis (25) . Therefore, we examined mammary gland morphology in control and Dox-treated MMTV tetLRH1 adult virgin female mice in estrus (Supplemental Figure 1B ) to determine whether LRH-1 induces a similar phenotype. The gross morphology of the mammary glands exhibited no overall structural differences between the 2 treatment cohorts, with both groups displaying developed mammary tree structures that extended beyond the lymph node and the presence of terminal end buds (data not shown). However, Dox-treated MMTV tetLRH1 mammary glands exhibited a poorly branched epithelial tree with rudimentary, thin ducts and a significant decrease in lateral buds compared with those in control animals ( Figure 5, L and N) . Quantification of lateral bud numbers revealed a 3-fold reduction at 3 weeks (P Ͻ .01) and a 2-fold reduction at 3 months (P Ͻ .01) compared with those in age-matched, vehicle-treated mice ( Figure 5, M and O) . Body weights and vaginal smears of animals after 3-month Dox treatment were analyzed and showed no difference, suggesting that the phenotype was due to activation of the hLRH-1 transgene and not in- Figure 1C; control n ϭ 4, Dox n ϭ 4).Thus, conditional expression of hLRH-1 in mouse mammary gland did not affect ductal proliferation but produced a lateral end bud phenotype remarkably similar to that induced by TGF-␤ overexpression.
Discussion
LRH-1 functions as a transcription factor to regulate steroidogenesis, cholesterol, and bile acid metabolism. It also promotes tumor cell proliferation in gastric, intestinal, hepatic, pancreatic, and breast cancers (4, 5, 12, 26, 27) . In breast cancer, a well-characterized action of LRH-1 is the activation of aromatase transcription in tumor-associated stroma (9) . As observed in other tumor epithelial cell types, in the ER-positive MCF-7 breast cancer cell line, LRH-1 stimulates proliferation and the expression of genes such as GREB1 and cyclins D1 and E1 (12, 26) . Our previous work identified additional functions for LRH-1 in mediating cell motility and changes to the actin cytoskeleton structure and promoting invasiveness in normal and tumor breast epithelial cell lines (27) . These findings suggested that LRH-1 might be involved in other tumorpromoting pathways.
We identified LRH-1-regulated genes in MCF-7 cells in which LRH-1 was knocked down and in MMTV tetLRH1 mice in which human LRH-1 expression was induced by treatment with Dox in mammary epithelial cells. We discovered that TGF-␤2--and TGF-␤-regulated genes were among the genes most significantly altered (Supplemental Figure 3) . LRH-1 expression positively correlated with TGF-␤-1, -2, and -3 mRNA levels and active protein levels and increased Smad2/3 phosphorylation both in vitro and in vivo. Integrin ␣v␤6 requires the interaction of latent TGF-␤-binding protein to mediate the activation of latent TGF-␤ (28), annexin A1, involved in phosphorylation and nuclear translocation (29) , and p53, known to interact directly with Smad2/3 on target gene promoters (30) . We observed changes in expression of MMP3 and ␣-smooth muscle actin, known TGF-␤ targets (31) that have also been demonstrated previously as regulated by LRH-1 (2, 13) . Furthermore, we demonstrated that expression of TGF-␤1 and -2 transcript is higher in MCF-7 cells than in T47-D cells. These observations are consistent with previous studies showing secretion of lower TGF-␤1 protein in T47-D cells than in MCF-7 cells (32) .
Pathway analysis of LRH-1-regulated genes in MCF-7 cells and MMTV tetLRH1 mammary tissue highlighted that most of the altered genes were involved in the regulation of cell motility, structure, and cell-cell interaction, in line with observations from previous studies (13) . Taking these results together with the phenotype of altered mammary gland morphology in MMTV tetLRH1 mice, we conclude that the TGF-␤ pathway may be an effector of these LRH-1-mediated events. Indeed, the reduced lateral branching and budding observed in MMTV tetLRH1 with ectopic LRH-1 expression are similar in phenotype with effects in mammary glands from mice implanted with TGF-␤1 pellets (25, 33) . This result suggests that LRH-1 may have an inhibitory effect in lateral budding via activation of the TGF-␤-signaling pathway. It is well established that TGF-␤1 is a key regulator of mammary branching morphogenesis. Specifically, it reduces proliferation and differentiation of ductal end buds, an effect that is reversible to allow for the continual development and involution of mammary glands (25, 34, 35) .
The regulation of branching processes controlling extension of ductal branches and formation of alveolar within the mammary fat pad, is crucial for lactation. Altered branching morphogenesis and lateral budding observed in Dox-treated MMTV tetLRH1 also implies that LRH-1 may have other effects in different development contexts such as proliferation of end bud structures during pregnancy. Further work to establish the differential cellular effects on mammary development during pregnancy, lactation, and involution using the MMTV tetLRH1 is ongoing.
The 3 known mammalian isoforms TGF-␤-1, -2, and -3 elicit similar paracrine responses in regulating mammary development and are colocalized in intracellular regions and detected during all stages of mammary gland development (34) . Primarily TGF-␤ isoforms act similarly in governing ductal morphogenesis by influencing extracellular matrix deposition including collagen as observed in animals treated exogenously with TGF␤-1, -2, and -3 (33, 36, 37) . The increased accumulation of collagen around the mammary ducts in Dox-treated MMTV tetLRH1 animals compared with that in untreated animals may be attributable to the activation of TGF-␤ signaling pathways.
Basal TGF-␤2 levels in mammary tissue are low; however, its expression is strongly up-regulated during pregnancy-associated mammary gland development (38, 39) . TGF-␤3 appears to be the only isoform markedly expressed in myoepithelial cells, which form the outermost monolayer of mammary ducts (38) . The functional significance of myoepithelial cells, other than their role as a contractile tissue during pregnancy, is unclear. It has been suggested that myoepithelial cells are capable of reforming cap cells during formation of lateral branches and may be involved in amplification of basal lamina components (25, 34) . The up-regulation of TGF-␤3 by LRH-1 in myoepithelial cells may increase basal lamina components, contributing to inhibition of lateral branching and budding.
Our findings demonstrate a strong association between LRH-1 and TGF-␤ activity that has not been identified previously. LRH-1 belongs to the NR5A subclass of the nuclear receptor family, binding as a monomer to a nuclear receptor halfsite sequence consensus YCAAGGYCR (40) . ChIP studies indicated a direct interaction between LRH-1 and binding sites on the TGF-␤1 promoter region. We also observed an overlap of LRH-1 RE and AP1 response elements on the TGF-␤1 promoter region. Recent ChIP sequencing studies have shown LRH-1 interacting with AP1 factors c-fos and c-jun (41) . Together with studies showing that AP1 regions are responsible for TGF-␤1 autoinduction (42), our data suggest a possible interaction between LRH-1 and TGF-␤1. Further studies are needed to explore this interaction. Genes encoding the TGF-␤-1, -2, and -3 isoforms are located on separate chromosomes, and we analyzed the first 5-kb region of respective promoters to identify the LRH-1 half-site sequence consensus. We identified 11 putative LRH-1 binding sites on the TGFB2 and 6 on the TGFB3 gene promoters; however, further studies to confirm whether LRH-1 binds directly to these sites to activate transcription are yet to be undertaken.
LRH-1 is a critical factor in early embryonic development, essential for maintaining pluripotency by the regulation of Oct4 and Nanog expression via the Wnt signaling pathway. Interestingly, in breast cancer stem cells, TGF-␤ signaling appears to modulate stem cell phenotype and maintain pluripotency (43, 44) . In the context of breast tumors, the association between TGF-␤ and LRH-1 may be worth exploring in the context of disease progression. TGF-␤ can alter tight junction formation in mammary epithelium and induce signaling in a number of embryonic signaling pathways, including Wnt, Notch, and Hh pathways (45) , as well as the MAPK pathway (46) . The complexity of this crosstalk signifies the variety of process that may be regulated during mammary gland development and tumorigenesis and highlights the importance of further investigation into the role of LRH-1 in promoting mammary tumorigenesis. To date, the functions of LRH-1 in mammary epithelial cells have not been studied in vivo. Our data demonstrate that the ectopic expression of LRH-1 in mouse mammary glands leads to inhibition of lateral mammary ductal branching via the stimulation of TGF-␤ signaling. The TGF-␤ pathway was also regulated by LRH-1 in breast cancer cells. How LRH-1 exerts its effects on the processes of proliferation and differentiation in the normal mammary gland and tumor cells has important implications for both development and breast cancer.
